There was a time when specialty care drugs for orphan indications such as rare genetic diseases and certain cancers flew under the radar of payers, as specialty treatments accounted for a tiny slice of payers' overall spending on prescription meds. Times have changed.
Big Pharma has gotten in on the orphan drug game, and new biotech entrants have also joined the original clutch of key players. Developers must carefully calculate strategies for ensuring differentiation, payer support and patient access for orphan drug programs — even before getting the green light from regulators to begin sales.
Join this FiercePharma webinar and hear experts from orphan drug units explain how the commercial landscape of their field is changing, as well as:
How orphan drug specialists have optimized patient access
Glean the latest insights on working with payers and reimbursement
Get the pulse on the market and how competition brought key changes
Dan Thornton, Director, US Marketing, Shire HGT
Faraz Ali, Vice President, Head of Program Management and Commercial Development, bluebird bio
Jason Barron, Associate Director of Public Policy, NORD
Chuck Stevens, Vice President & General Manager, PAREXEL